By Jad Malaeb, Benzinga Chicago, Illinois --News Direct-- Cboe Global Markets, Inc. The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400. Individual stocks have seen some relief as well, particularly in the oil & gas, biotechnology and financial sectors, which continue to show bullish action compared to the general market. The current rally is likely influenced by the latest Consumer Price Index (CPI) and Producer Price Index (PPI) reports, both of which came in below expectations. This arguably indicates that the Federal Reserve’s monetary tightening policies are starting to work. Cboe Global Markets Inc. (BATS: CBOE) reports that all the exchange-traded funds (ETFs) and indices recorded in this series experienced a price decrease last week as the general market experienced a pullback in its short-term uptrend. Britain’s iShares Core DAX UCITS ETF (BIT: EXS1) and France’s Lyxor CAC 40 ETF (EPA: CAC) were the two exceptions, both experiencing slight increases in the prior week. The cryptocurrency market has largely mirrored its traditional counterparts, experiencing decreases in Bitcoin (CRYPTO: BTC), Ethereum (CRYPTO: ETH) and Solana (CRYPTO: SOL) — all of which have dropped in value following FTX’s collapse. With uncertainty brimming, Cboe highlights Biogen Inc. (NASDAQ: BIIB) as a chart that may have piqued investor interest following positive clinical trial results for their new Alzheimer’s drug. Next week will be huge for the fashion retail sector, with many of Wall Street’s top firms reporting earnings. Cboe has compiled a list of earnings for investors to keep an eye on at the bottom of this report. Keep scrolling to learn more. Quick BitesExchange-Traded Funds The SPDR S&P 500 ETF (NYSEARCA: SPY) decreased by 0.62% over the previous week. The Invesco QQQ Trust Series 1 (NASDAQ: QQQ) decreased by 1.09% over the previous week, mirroring the SPY’s movements. The iShares Russell 2000 ETF (NASDAQ: IWM) decreased by 1.70% over the previous week. The Cboe Volatility Index™ (INDEXCBOE: VIX) closed at 23.11 last week, a slight increase over last week. World Markets The iShares CoreMSCI Europe ETF (NYSEARCA: IEUR) decreased by 0.63% week-on-week. The iShares FTSE 100 UCITS ETF (LSE: ISF) increased by 0.95% week-on-week. The Lyxor CAC 40 ETF (EPA: CAC) increased by 0.71% week-on-week. Chart Of The Week: BIIB This photo was taken from the TradingView platform Shares of Biogen skyrocketed on Sept. 22nd after the company announced positive clinical trial results for their Alzheimer’s drug lecanemab. The company said their drug met all key secondary endpoints with highly statistically significant results. These results have brought Biogen closer to a Federal Drug Agency (FDA) approved Alzheimer’s drug, a feat several biopharmaceutical companies are competing to achieve. Investors responded enthusiastically to this information. Biogen’s trading volume on the 28th of September hit 7.111 million shares, a 1,500% positive deviation off of the 50-day average trading volume of 331,000. The stock’s price slingshotted 50% overnight – rising to $284 a share – and, since then, has drifted toward $300. According to Grand View Research, the Alzheimer’s therapy market was valued at $4.04 billion in 2021 and is expected to grow at a 16.2% compound annual growth rate from 2022 to 2030. Major Cryptocurrencies Bitcoin has decreased by 0.33% since the previous week, consolidating after FTX’s collapse. Ethereum has decreased by 6.4% since last week. Solana has decreased by 6.91% since last week. Upcoming Earnings Releases A number of companies report earnings next week, including: Company Earnings per share (EPS) estimate Dell Technologies Inc. (NYSE: DELL) $ 1.61 Zoom Video Communications Inc. (NASDAQ: ZM) $ 0.84 Urban Outfitters Inc. (NASDAQ: URBN) $ 0.42 Best Buy Co. (NYSE: BBY) $ 1.03 Helmerich & Payne, Inc. (NASDAQ: HP) $ 0.84 Abercrombie & Fitch (NYSE: ANF) -$0.14 Dick’s Sporting Goods Inc. (NYSE: DKS) $ 2.24 Nordstrom Inc. (NYSE: JWN) $ 0.15 Click here for more weekly insights by Cboe. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Michele Ormont [email protected] Company Website https://www.cboe.com/ View source version on newsdirect.com: https://newsdirect.com/news/cboes-weekly-market-recap-nov-14-18-biogens-alzheimers-drug-captures-investors-attention-371254297
CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...